Amalgam filling phase-out hits SDI's sales
Filling material supplier SDI pre-reports a flat result, partly because of declining amalgam sales
Perspiring investors wipe more than 40% off Botanix share price after US market update
FDA approves Cochlear's 'smart' implant system
Veteran dental materials supplier SDI (ASX:SDI) has flagged soft numbers for the 2024-25 year, mainly because the world is phasing out amalgam filling material that contains mercury.
With pre-reporting results due out on August 28, SDI said revenue for the year to June would come in at $111 million, 0.2% lower than the previous year.
Net profit will be $10-10.4 million, compared with $10.4 million previously.
SDI cites a 20.45% decline in amalgam sales, most pronounced in North America and Europe.
Amalgams account for 13% of SDI's sales, compared with 16% last year and 23% five years ago.
In absolute terms, however, SDI's amalgam sales have been steady at $18 million – a trend not lost on anti-mercury proponents.
Overall SDI's European and Brazilian sales grew 7.2% and 9.9% respectively in local currency terms, offset by overall weakness in the Middle East and Asia.
While an ugly grey, amalgam fillings remain popular because of their strength.
But given they contain 50% mercury, their use is either being restricted or banned.
The European Union is phasing out the use of the material by 2030, while Sweden and Norway have banned it.
Elsewhere, Moldova, Mongolia, some Persian Gulf states, and the Philippines have also outlawed the grey gob filler.
A global treaty, the Minamata Convention on Mercury aims to phase out dental amalgam but doesn't impose a complete ban.
A signatory to this accord, Australia has restricted the use of bulk mercury in dental practices.
Today's SDI release makes no mention of Stela, its replacement product that is pearly white and with the strength of an amalgam filling.
Quiet export achiever
For more than 50 years, SDI developed and exported dental supplies from its base in eastern Melbourne.
Now the company's chair, Jeffery James Cheetham founded the company, then known as Southern Dental Industries in 1972.
SDI listed on the ASX in 1985 and is now run by Cheetham's daughter Samantha.
And speaking of medtech exporters, Adelaide based optical device stalwart Nova Eye Medical (ASX:EYE) has reported June half sales (excluding China) of US$9.57 million, thus snugly meeting guidance of US$9-10 million.
Nova's full year revenue was US$18.4 million, up 21% with the US accounting for US$14.2 million (up 25%).
Nova shares gained an eye-catching 12%.
Botanix US update hits a sweaty note
Addressing a webcast of more than 600 investors, Botanix Pharmaceuticals (ASX:BOT) announced it had chalked up $25 million of gross US Sofdra sales since launching the drug in January.
Despite this impressive take-up, punters wiped more than 40% – or $240 million – from the company's market cap.
The reason appears to be a higher-than-expected gap between those gross sales and the amount the company pockets.
Sofdra treats primary axillary hyperhidrosis (PAH): excessive underarm sweating beyond what's required to regulate body temperature.
The company reports that dermatologists wrote 16,000 prescriptions for 6700 patients, with refill rates of 3.4 per year.
This compares with the sector average of two refills per year.
'We are in line with some of the best derm launches out there,' Botanix executive director Howie McKibbon said.
A tube of Sofdra – enough for a month's supply – costs US$300 to US$400.
Patients enrolled on the company's auto-refill program had a 95% adherence rate, "a measure of how consistently patients obtain refills for their prescribed medications.'
Otherwise, 79% of patients adhered to the treatment.
As of June, Sofdra's prescriber base stood at 2300 docs.
Now to profitability
In June the company's gross yield to to net revenue stood at 23%, up from 13% in January. This reflects the amount pocketed by intermediaries by way of discounts, rebates and such.
While Botanix's take seems low, management says its share of the pie is industry leading.
The company targets a 30-40% range, compared to generic skin offerings that might only attract a 10-15% margin.
Management also said the proportion of reimbursed scripts has also grown to 39% of the total, compared with 26% at the start of January.
Meanwhile, Botanix is expanding its US reach from an initial reach of 27 to 33, with plan underway to increase the number to 50.
The company also reassured investors that it was not planning a capital raising and that Trump's tariffs likely would be immaterial.
Botanix currently is holding an event series called 'Summer of Sweat'.
This sounds like a Woodstock style festival but it's a forum for Botanix execs to meet with healthcare providers across 14 US cities.
Woodstock went ahead despite torrential rain and we're sure management will rock on despite the setback.
Cochlear hears good news from the FDA
In a disclosure Hemingway-esque in its brevity, Cochlear (ASX:COH) today said the FDA has approved its next-generation Nucleus Nexa implants – 'the world's first and only smart cochlear implant system' – as well as its Nucleus Kanso and Kanso 3 Nexa sound processors.
Cochlear hopes the refreshed products will staunch recent weakness in its developed country sales.
The company launched the 'Nucleus Nexa System' – the implant/processor comb -in Europe and the Asia Pacific last month.
It plans to launch the products in the US in the current quarter.
Syntara's new name will grow on us
Most investigative drug names are odd for a reason, because they need to be unique and avoid bold therapeutic claims.
Come to think of it, they can't mean much at all – as Syntara's (ASX:SNT) new drug name would attest.
The World Health Organisation has ascribed an International Non-Proprietary Name (INN) to Syntara's myelofibrosis drug candidate, SNT-5505.
Commonly known as a generic name, an INN is a globally recognised, unique name for a pharmaceutical substance or active ingredient.
The new moniker for SNT-5505? Amsulostat.
Syntara CEO Gary Phillips says the name reflects the drug's 'unique mechanism of action and clinical promise'.
We're sure it will grow on everyone over time – and we've heard worse.
Originally published as Health Check: Dental supplier faces the hard tooth that amalgam fillings are on the way out
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mercury
an hour ago
- Mercury
PNN secures Pocitos water drilling approval
Special Report: Power Minerals has received the green light to carry out hydrological drilling to advance its Rincon Lithium joint venture project in Argentina's Salta province. Power Minerals gets approval for hydrological drilling at Rincon joint venture in Argentina's Salta province Drilling targets industrial water source needed for direct lithium extraction operations at Pocitos project Navigate Energy poised to release US$4 million investment commitment for JV The drilling at the Pocitos project within the JV area is aimed at securing an industrial water source, which is essential for direct lithium extraction operations. This program will explore freshwater resources within the extensive alluvial fan northeast of the Pocitos salar. Finding a source of industrial water will strengthen Power Minerals' (ASX:PNN) plan to establish the Rincon JV with Navigate Energy as a lithium carbonate production hub in South America. 'Moving ahead with drilling to identify an industrial water source helps us progress our development plans,' managing director Mena Habib said. 'Pocitos has the potential to offer this required water source and we look forward to seeing what drilling will reveal.' Pocitos project The Pocitos project sits within Salta province in South America's famed lithium triangle, a region recognised as the go to destination for lithium brines drawing majors and juniors alike. Pocitos itself benefits from direct access to the General Belgrano Railway connecting to Pacific (Chile) and Atlantic (Argentina) ports, integration with existing natural gas pipelines and connection to the Cauchari and Altiplano solar farms, and support from a reliable legal and regulatory mining framework along with a skilled workforce. Ongoing infrastructural improvements such as the paving of highway Route 27, a planned high-voltage electrical connection from Cauchari, and a 435-hectare industrial park at Pocitos, add further to the project's strength. PNN adds that integration of the Rincon JV entity is nearing completion, which will release US$4 million in investment from Navigate Energy as part of its commitment. This includes funding dedicated to both Rincon and Pocitos development activities. The broader Rincon JV area has a JORC resource of 292,564t lithium carbonate equivalent at a lithium concentration of 248mg/L. Development will be through the use of direct lithium extraction, which has been proven to deliver substantial cost, water, and energy savings compared to traditional methods. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Power Minerals gains water drilling approval to advance Pocitos lithium production hub
Sydney Morning Herald
an hour ago
- Sydney Morning Herald
EU and US agree to trade deal with 15% tariffs for European exports
Frankfurt: The European Union has ended months of dispute with US President Donald Trump by accepting a deal that imposes 15 per cent tariffs on billions of dollars in exports, submitting to the terms out of concern he might otherwise punish Europe with higher penalties. The outcome appears set to lift prices for American consumers and hurt sales for European exporters, in the latest example of global brinksmanship as Trump forces tariffs on major economies in the hope of raising huge sums of revenue for the US government. In a surprise addition to the deal, the EU agreed to buy energy worth $US750 billion from the US over the years ahead – part of the bloc's broader objective of reducing reliance on Russian gas. Trump said the EU would also invest $US600 billion more in the US economy, echoing a vague investment pledge in a trade deal with Japan last week. The deal was unveiled in Scotland on Sunday during Trump's visit to his golf estates, as hundreds of protesters gathered to object to his visit, while supporters chanted his name outside some of his events. Loading 'I think this is the biggest deal ever made,' Trump told reporters after he emerged from talks with European Commission President Ursula von der Leyen. European industries were divided on the trade dispute over recent weeks, with German car makers anxious to gain a deal because of the threat to their sales from even higher tariffs, while French industry canvassed retaliation against US demands. Von der Leyen confirmed the 15 per cent tariff applied 'across the board' and framed the outcome as a win for stability.
News.com.au
2 hours ago
- News.com.au
Health Check: Clarity shares surge after ‘fast and sizeable' $203m raise
• Clarity Pharmaceuticals rocket up to 12% after its blitzkrieg placement • Artrya, Botanix and Imricor are among today's quarterly updates • Lumos outlines US market potential Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) has surprised investors with a monstrous $203 million institutional placement, struck at a 15% premium to the company's 15-day average price. None will be more surprised than the short sellers, who account for close to 10% of the company's register. Executive chairman Dr Alan Taylor says the 'fast, well executed and sizeable' placement was to a small group of local instos 'close to the company'. Unusually, no-one blabbed and the shares did not enter trading halt. 'I have never done a deal that fast,' Taylor told Stockhead. 'A week ago, I would have said we were not doing a capital raising, but there was a lot of interest from a very concentrated group . "The raising was struck at $4.20 a share, a 2.2% premium to Friday's close and a hefty 18% more than the 15-day weighted average price. The raising comes amid what Taylor dubs 'an incredibly tumultuous' period driven by US politics, as well as some 'unfortunate news' from local biotechs (read: Opthea's (ASX:OPT) phase III trial failure). In December Clarity shares were promoted to the ASX200, which was good for enhancing Clarity's profile. But it also contributed to shorting activity. Given the share gains, these investors are likely to be buying up stock to cover their positions. Well funded for trials Clarity emerges from the raising with $288 million of cash, which will fund the company's packed slate of trials. These include two phase III prostate cancer imaging trial aimed at US Food & Drug Administration registration, dubbed Amplify and Clarify. Amplify is for patients with biochemical recurrence post treatment; Clarify is for those intended to undertake prostate removal. Both are open label and single-arm (with no placebo and comparison cohort). Another trial on the sidelines, Co-PSMA compares Clarity's tool with the standard-of-care diagnosis methods. The company expects an initial data readout on this one before the end of the year, with Amplify and Clarify readouts next year. Clarity listed in August 2021, raising a record $92 million at $1.40 apiece. The company then went one better in April last year, raising $121 million in a right issue and placement (at $2.55 a share). The raising is one of the biggest in biotech history and the chunkiest since Mesoblast gathered $260 million in a placement in January. Imricor confident of US approval Imricor Medical Systems (ASX:IMR) is confident of US approval of its world-first ablation catheter this year. We say 'world's first' because the device is the only one capable of being guided by magnetic resonance imaging (MRI), as opposed to x-ray fluoroscopy. Imricor's submission is by way of a staggered, modular process. The company reports the second module is under review and the company expects to submit the third module in the December quarter. 'We expect a steady string of 510(k) product submissions and approvals , which in turn helps accelerate the commercial launch across the US," the company says. In the March quarter European regulators approved Vision-MR, the company's updated catheter for type 1 atrial flutter, under the Continent's bolstered Medical Devices Regulation. In the June quarter they also gave the nod to Advantage-MR, which enables a physician to use a recording system and cardiac stimulator while ablating. The European gatekeepers also approved Northstar, 'the world's only MRI-native 3D mapping and guidance system.' With June quarter receipts of US$85,000, Imricor is yet to start European sales in earnest. The company posted June quarter outflows of US$4.43 million, taking cash on hand to a handy US$50.3 million. Sales will flow this quarter, says plaque-buster Artrya Still on matters of the heart, Artrya (ASX:AYA) expects first US subscription revenue from its AI-enabled Salix coronary plaque detection platform in the current quarter. An algorithm-based artificial intelligence tool, Salix detects the plaque deposits on x-ray coronary computed tomography angiograph (CCTA) images. Despite vulnerable plaque being the cause of most heart attacks, plaque currently is not routinely reported in cardiac imaging and diagnostics. It's difficult to detect with the naked eye in traditional images. In March the FDA approved Salix Coronary Anatomy (SCA) and Artrya is now seeking the agency's consent for Salix Coronary Plaque (SCP). SCP expands applicability to detecting and quantifying coronary arterial plaque for those patients who have undergone a coronary CT angiogram. The SCP module will integrate automatically with SCA. SCA already is being trialled and in clinical use, by Artrya's customers and partners, generating a symbolic $8000 in receipts of the quarter. Earlier this month Artrya inked its first commercial deal, a five-year minimum $600,000 contract with Tanner Health. Artrya expended $5.44 million for the quarter, taking cash to $11.3 million. The company expects a $4.5-5 million R&D tax refund by the end of the year. Botanix reports 600% revenue uptick Botanix Pharmaceuticals (ASX:BOT) reports net revenue of $4.3 million from US sales of Sofdra, compared with $700,000 in the March quarter. The company launched the drug – which treat an excessive sweating condition – in the US in March quarter. The 'net' descriptor is relevant, because some folks were taken aback after the company's July 8 update which showed the extent to which other parties clipped the revenue ticket, Doctors wrote 7053 prescriptions during the quarter, 324% higher than 2975 in the March stanza. The number of prescribers rose 11%, to 2316 from 1075 previously. Launching a drug is not cheap and the company burnt $28.4 million, leaving cash of $64.9 million. Let's be CLIA, it's a big market says Lumos Lumos Diagnostics (ASX:LDX) expects its Febridx virus-versus-bacterial diagnostic tool to capture eight million US patients within three years, via its company making distribution deal with Phase Scientific. Announcing the tie up on July 16, Lumos said the deal would deliver US$2 million immediately – cash the company has, indeed, banked – and a total of US$317 million ($487 million) over six years. Detailing the arrangement on Friday, CEO Doug Ward said the company expected a total addressable market of 80 million, assuming the FDA grants a so-called CLIA waiver. The number consists of patients present with acute respiratory infections. 'Our thinking is that in years two to three we will be 2% or 3% of that,' Ward said. 'In year six, that ramps up to 10%.' As in Clinical Laboratories Improvement Act, CLIA requires hospitals and labs to operate under government accreditation Exemption from CLIA enables parties such as GPs and medical assistants to carry out the low-complexity lateral-flow assays. In financial terms, the market increases tenfold, to US$1 billion a year. Lumos is carrying out a trial to support its FDA application and has recruited close to 120 of the bacterial-positive patients required. Coming back to the finances, Phase pays Lumos another US$1.5 million on its CLIA application, expected next month. On FDA approval, Phase pays another US$5 million. That leaves US$308 million over years three to six, which Ward says is based on minimum order volumes. Lumos shares rocketed 133% on the back of the Phase announcement and have held their gains.
